The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global mRNA vaccines and therapeutics market potential is expected to reach a value of US$ 9.41 Billion in 2021. Looking forward, IMARC Group expects the market to register a CAGR of 10.5% during 2021-2026, reaching a value of US$ 15.49 Billion by 2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Messenger Ribonucleic Acid (mRNA) refers to a single protein-coding gene in the genome that acts as a basis for protein synthesis within the cells. mRNA vaccines and therapeutics combine the desirable immunological properties and are prepared in laboratories using mammalian cells. Some of the common types of vaccines and therapeutics include self-amplifying, non-replicating, in vivo self-replicating and in vitro dendritic cell non-replicating mRNA. They are injected into the body to trigger virus-detecting immune sensors and produce viral antigen proteins within the cells. This aids in enhancing the body’s immunity by improving B- and T-cell responses.
The rising prevalence of medical ailments, such as diabetes, tuberculosis, cancer and cardiovascular diseases (CVDs), is one of the key factors driving the growth of the market. The increasing demand for therapeutic medicines and vaccines for Ebola, influenza, Human Immunodeficiency Virus (HIV) and other viral infections is also providing a boost to the market growth. In comparison to conventional medicines, mRNA vaccines and therapeutics are developed using advanced technologies that are more effective against pathogens, have higher potency, enhanced immunogenicity and are relatively more cost-effective. Additionally, improvements in the lipid nanoparticle formulations for in-vivo systemic delivery of mRNA are also creating a positive outlook for the market. Pharmaceutical companies are investing in mRNA technologies as they can combine multiple molecules into a therapeutic medicine, which is acting as another major growth-inducing factor. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with improvements in the healthcare technologies, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global mRNA vaccines and therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application and end user.
Breakup by Vaccine Type:
Breakup by Treatment Type:
Breakup by Vaccine Manufacturing:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Arcturus Therapeutics Inc., BioNTech SE, CureVac AG, Etherna, ethris GmbH, GlaxoSmithKline PLC, Moderna Therapeutics Inc., Translate Bio Inc., Argos Therapeutics, Inc., Sangamo Therapeutics Inc. and Pfizer Inc, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Vehicle Type, Treatment Type, Vaccine Manufacturing, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Arcturus Therapeutics Inc., BioNTech SE, CureVac AG, Etherna, ethris GmbH, GlaxoSmithKline PLC, Moderna Therapeutics Inc., Translate Bio Inc., Argos Therapeutics, Inc., Sangamo Therapeutics Inc. and Pfizer Inc|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at